Wegovy 0.25 mg solution for injection in pre-filled pen

DRUG4 trials

Sponsors

Region Hovedstaden, Novo Nordisk A/S

Conditions

Cannabis dependence (Cannabis Use Disorder or CUD)Non-alcoholic steatohepatitis (NASH)Obesity and Heart Failure with reduced Ejection FracitionObesity and overweightUnipolar depression Overweight and obesity

Phase 2

FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity

RecruitingCTIS2023-503753-35-01

Region HovedstadenObesity and Heart Failure with reduced Ejection Fracition

Start: 2024-03-20Target: 100Updated: 2025-08-22

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

Not yet recruitingCTIS2025-524163-21-00

Region HovedstadenCannabis dependence (Cannabis Use Disorder or CUD)

Target: 100Updated: 2026-03-30

Phase 3

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Active, not recruitingCTIS2023-506962-30-00

Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)

Start: 2021-03-29Target: 219Updated: 2025-11-11

Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.

RecruitingCTIS2024-511734-13-04

Region HovedstadenObesity and overweight, Unipolar depression Overweight and obesity

Start: 2025-05-15Target: 120Updated: 2025-12-23